검색
Spero Therapeutics Inc
SPRO관심 목록에 추가
2.200USD
-0.020-0.90%
종가 07/02, 13:00（ET）시세는 15분 지연됩니다
127.38M시가총액
7.92P/E TTM
자세한 내용은 Spero Therapeutics Inc 회사
Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on identifying and developing novel treatments for rare diseases and diseases caused by multi-drug resistant (MDR) bacterial infections with unmet need. Its product candidate SPR720 is an investigational, chemically stable phosphate ester prodrug that is converted in vivo to SPR719 for the treatment of nontuberculous mycobacterial (NTM) pulmonary disease. Its clinical stage product candidate, tebipenem HBr is an investigational oral carbapenem antibiotic being developed for the treatment of complicated urinary tract infections (cUTIs) including acute pyelonephritis (AP) to help patients potentially reduce duration of in-patient therapy.
Spero Therapeutics Inc 정보
종목 코드 SPRO
회사 이름Spero Therapeutics Inc
상장일Nov 02, 2017
CEORajavelu (Esther)
직원 수32
유형Ordinary Share
회계 연도 종료Nov 02
주소675 Massachusetts Ave Ste 14
도시CAMBRIDGE
증권 거래소NASDAQ OMX - NASDAQ BASIC
국가United States of America
우편 번호02139-3309
전화18572421600
웹사이트https://sperotherapeutics.com/
종목 코드 SPRO
상장일Nov 02, 2017
CEORajavelu (Esther)
Spero Therapeutics Inc의 회사 임원진
이름
이름/직위
직위
주식 보유
변동
Dr. Ankit Mahadevia, M.D.
Dr. Ankit Mahadevia, M.D.
Non-Executive Director
Non-Executive Director
364.22K
-1.80%
Mr. Timothy (Tim) Keutzer
Mr. Timothy (Tim) Keutzer
Chief Operating Officer
Chief Operating Officer
335.13K
+55.82%
Ms. Esther Rajavelu
Ms. Esther Rajavelu
President, Chief Executive Officer, Chief Financial Officer, Treasurer and Chief Business Officer
President, Chief Executive Officer, Chief Financial Officer, Treasurer and Chief Business Officer
229.84K
-10.98%
Dr. Milind S. Deshpande, Ph.D.
Dr. Milind S. Deshpande, Ph.D.
Independent Director
Independent Director
71.45K
-27.99%
Mr. Frank E. Thomas, CPA
Mr. Frank E. Thomas, CPA
Independent Chairman of the Board
Independent Chairman of the Board
55.00K
-36.36%
Ms. Cynthia Smith
Ms. Cynthia Smith
Independent Director
Independent Director
55.00K
-36.36%
Ms. Kathleen Tregoning
Ms. Kathleen Tregoning
Independent Director
Independent Director
55.00K
-36.36%
Dr. Patrick Volkert Jozef Johannes Vink, M.D.
Dr. Patrick Volkert Jozef Johannes Vink, M.D.
Lead Independent Director
Lead Independent Director
--
--
Dr. John C. Pottage, Jr., M.D.
Dr. John C. Pottage, Jr., M.D.
Independent Director
Independent Director
--
--
Mr. Scott T. Jackson
Mr. Scott T. Jackson
Independent Director
Independent Director
--
--
이름
이름/직위
직위
주식 보유
변동
Dr. Ankit Mahadevia, M.D.
Dr. Ankit Mahadevia, M.D.
Non-Executive Director
Non-Executive Director
364.22K
-1.80%
Mr. Timothy (Tim) Keutzer
Mr. Timothy (Tim) Keutzer
Chief Operating Officer
Chief Operating Officer
335.13K
+55.82%
Ms. Esther Rajavelu
Ms. Esther Rajavelu
President, Chief Executive Officer, Chief Financial Officer, Treasurer and Chief Business Officer
President, Chief Executive Officer, Chief Financial Officer, Treasurer and Chief Business Officer
229.84K
-10.98%
Dr. Milind S. Deshpande, Ph.D.
Dr. Milind S. Deshpande, Ph.D.
Independent Director
Independent Director
71.45K
-27.99%
Mr. Frank E. Thomas, CPA
Mr. Frank E. Thomas, CPA
Independent Chairman of the Board
Independent Chairman of the Board
55.00K
-36.36%
Ms. Cynthia Smith
Ms. Cynthia Smith
Independent Director
Independent Director
55.00K
-36.36%
자주 묻는 질문
Spero Therapeutics Inc의 상위 5대 주주는 누구인가요?
Spero Therapeutics Inc의 상위 5대 주주는 다음과 같습니다: Dr. Ankit Mahadevia, M.D.
Spero Therapeutics Inc(SPRO)의 주식을 보유한 기관은 몇 개입니까?
2026Q1 기준으로, Spero Therapeutics Inc의 주식을 보유한 기관은 총 117곳이며, 이들이 보유한 주식의 총 가치는 약 11.81M로 전체 발행 주식의 20.40%를 차지합니다. 이는 2025Q4 대비 -1291189.00 증가한 수치입니다.
Spero Therapeutics Inc의 최대 수익원은 무엇인가요?
2026Q1 기준, Spero Therapeutics Inc의 Collaboration Revenue Related Party 부문이 가장 높은 매출을 기록했으며, 금액은 47.03M로 전체 매출의 70.41%를 차지했습니다.